CRMD
Cormedix Inc. Health Care Pharmaceutical Preparations Russell 3000
$5.70Close
$451.8MMarket cap
$5.70 – $12.7352-week range
Nov 11, 2026Next report
Highlights
Cautions
- Not in an uptrend 1 of 8 trend conditions
- Lagging the market RS 8 · weaker than 92% of stocks over 12 months
- Far from its high 55% below its 52-week high
- Results soon Nov 11, 2026, in 10 days
- Financial distress Altman Z″ in the distress zone
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
55%
1wk
down 27.4%
price change
1mo
down 26.0%
price change
12-month return
down 51%
market up 11% ·
its own down 60%
F-score
5 / 9
Mixed
Altman Z
1.60
Elevated risk
P/E
2.8×
price / earnings
PEG
—
P/E / EPS growth
P/B
1.1×
price / book
Earnings yield
up 48.9%
EBIT / enterprise value
Cheaper than
97%
of the market · markedly cheap
Revenue growth
up 617%
year on year
EPS growth
up 2%
latest quarter · -37 pts
Sales growth
up 157%
latest quarter · -70 pts
ROE
up 67%
return on equity
Free cash margin
up 55%
$172.8M FCF
D/E
0.00
long-term debt / equity
Net debt / EBITDA
-1.0×
net cash
Interest cover
—EBIT / interest
Piotroski tests
- took on more long-term debt
- short-term liquidity weakened
- issued more shares
- gross margin narrowed
- profitable on its assets
- generating cash from operations
- profitability improving
- profits backed by cash
- assets working harder
Repair signals
- FCF turned positive ($-51M → $173M)
Trade setup
ATR%
7.9%
$0.45 a day · 2×ATR $4.80
RS
8 / 99
vs the universe
Trend
1 / 8
trend template
Relative volume
6.9×
vs 50-day average
Up/down volume
0.85
50 sessions
Implied move
—
no option chain · report Nov 11, 2026
Trend template · 1 of 8
- 150-day average above the 200-day: passes
Screen verdict
Did not qualify for any screen.
Warning signs
- Bankruptcy model reads distressed The Altman score sits inside the range historically associated with financial distress. It is used here only to exclude, never to rank, and it is a statistical band rather than a prediction about this company.
- Shareholders diluted The share count rose 23.1% over the year, from 64m to 79m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
- Gross margin narrowing Gross margin fell from 92.7% to 88.5%. The company is keeping less of each dollar of sales than it did a year ago.
Last reported
Aug 13, 2026
Last shock
Oct 30, 2026-25% in one session6.2× volumeno filing matched0% since
Financials
- Gross 88%
- Net 52%
- Free cash 55%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $239,231 | $190,936 | $65,408 | — | $43.5M | $311.7M |
| Gross margin | 14% | 22% | 94% | — | 93% | 88% |
| Operating income | -$27.2M | -$29.4M | -$30.6M | -$49.0M | -$22.4M | $150.1M |
| Net income | -$22.0M | -$28.2M | -$29.7M | -$46.3M | -$17.9M | $163.1M |
| Net margin | -9208% | -14775% | -45410% | — | -41% | 52% |
| Earnings per share | — | -$0.75 | -$0.74 | -$0.91 | -$304.56 | $2,030.37 |
| Free cash flow | -$22.1M | -$22.6M | -$24.6M | -$38.7M | -$50.7M | $172.8M |
| Free cash margin | -9230% | -11826% | -37574% | — | -117% | 55% |
| Cash | $41.9M | $53.3M | $43.1M | $43.6M | $40.7M | $144.8M |
| Long-term debt | — | — | — | — | — | $150,000 |
| Shareholders' equity | $44.2M | $62.8M | $55.1M | $70.1M | $84.7M | $405.3M |
| Shares outstanding | 33.56m | 38.09m | 42.82m | 54.94m | 64.41m | 79.26m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 13, 2026 | Quarterly ↗ | Jun 30, 2026 | 44d |
| May 14, 2026 | Quarterly ↗ | Mar 31, 2026 | 44d |
| Mar 5, 2026 | Annual ↗ | Dec 31, 2025 | 64d |
| Nov 12, 2025 | Quarterly ↗ | Sep 30, 2025 | 43d |
| Aug 7, 2025 | Quarterly ↗ | Jun 30, 2025 | 38d |
| May 6, 2025 | Quarterly ↗ | Mar 31, 2025 | 36d |
| Mar 25, 2025 | Annual ↗ | Dec 31, 2024 | 84d |
| Oct 30, 2024 | Quarterly ↗ | Sep 30, 2024 | 30d |
| Aug 14, 2024 | Quarterly ↗ | Jun 30, 2024 | 45d |
| May 9, 2024 | Quarterly ↗ | Mar 31, 2024 | 39d |
| Mar 12, 2024 | Annual ↗ | Dec 31, 2023 | 72d |
| Nov 14, 2023 | Quarterly ↗ | Sep 30, 2023 | 45d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 19, 2026 | Regulation FD ↗ |
| Aug 13, 2026 | Results ↗ |
| Aug 7, 2026 | Other events ↗ |
| Jul 2, 2026 | Other events ↗ |
| Jul 1, 2026 | Auditor change ↗ |
| Jun 24, 2026 | Shareholder vote ↗ |
| Jun 8, 2026 | Regulation FD ↗ |
| May 14, 2026 | Results ↗ |
| Apr 27, 2026 | Regulation FD ↗ |
| Mar 6, 2026 | Regulation FD ↗ |
| Mar 5, 2026 | Results ↗ |
| Jan 8, 2026 | Results · Director or officer change · Other events ↗ |